Progenika Inc

PROGENIKA’s BLOOD GROUP GENOTYPING TEST AVAILABLE THROUGH ARUP LABORATORIES

Cambridge, MA, October 22, 2009 – Progenika, Inc. today announced that it has entered into an agreement with ARUP Laboratories (ARUP) of Salt Lake City, UT, to provide blood group genotyping reference laboratory services to ARUP to determine patient red blood cell antigen profiles when serology has logistic and functional limitations. Progenika’s blood group genotyping microarray, which simultaneously detects over 100 genetic variants in the nine blood group systems that are most relevant to transfusion safety, overcomes these serological limitations.

Read more...
 
  1. home
  2. Products
  3. ADH test

Autosomal Dominant Hypercholesterolemia

  • Early detection and treatment of ADH is key to improving patient outcomes
  • Patients with ADH have access to effective treatments that can lower cholesterol levels by up to 60%.

Autosomal Dominant  Hypercholesterolemia (ADH) is a genetic disorder that affects approximately 1 in 500 persons worldwide.It comprises Familial Hypercholesterolemia (FH) and Familial Defective Apolipoprotein B (FDB).

Clinically, patients with ADH have a higher risk of developing coronary artery disease and atherosclerosis at an early age due to mutations on genes coding for proteins responsible for removing cholesterol from the blood.

accurate, rapid and cost-effective testing...

According to the American Heart Association and the World Health Organization, genetic testing is the gold standard for diagnosis. 

 Some of the advantages of a genetic-based confirmation are:

  • Identification of asymptomatic children and relatives
  • Earlier treatment
  • More effective treatment
  • Greater treatment regimen adherence
For healthcare professional For individuals